fda drug safety communication semaglutide naion 2025 use in patients with diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, and 4 years. https://ja.ma/4iZkMeV GLP-1 Receptor Agonists and vision

Will my insurance cover maintenance doses

What dietary changes can help manage acid reflux on semaglutide

But visibility does not equal quality

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database

And without the continued downward trajectory that motivated continued use, exploring alternatives with different mechanisms becomes an appealing strategy to break through stalled progress

Some patients on semaglutide have developed gallbladder disease, including cholecystitis (gallbladder inflammation)